Siemens Healthineers AG Acquires Advanced Accelerator Applications to Boost PETNET Solutions
Germany-based Siemens Healthineers AG (ETR: SHL) has announced the completion of its acquisition of Advanced...
Company
Angitia Biopharmaceuticals Secures USD 120 Million in Series C Financing for Musculoskeletal Treatments
Angitia Biopharmaceuticals, a provider of solutions for musculoskeletal diseases operating out of Guangzhou, China, and...
MDHC Life Technologies Secures Series C++ Funding to Boost Consumer Healthcare and Life Sciences
China-based Contract Development Manufacturing Organization (CDMO) MDHC Life Technologies (Kunshan) Co.,Ltd has reportedly raised hundreds...
Bayer AG’s Shanghai Co.Lab to Host Epigenic Therapeutics and Peers for CGT Innovation
Germany-based Bayer AG (ETR: BAYN) has announced that Chinese companies Epigenic Therapeutics, Shanghai Immunocan Biotech...
AstraZeneca’s Lynparza Shows Sustained Improvements in OlympiA Phase III Study
UK pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) has updated data from the Phase III OlympiA...
Sanofi Receives FDA Fast-Track Designation for Influenza and COVID-19 Combo Vaccine Candidates
Sanofi (NASDAQ: SNY) has announced that it has received Fast-Track Designations from the US Food...
Youjia Biomedical and Livzon Pharmaceutical Group Ink Licensing Deal for siRNA Drug
China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd. has signed a licensing agreement with compatriot firm...
Bayer AG to Acquire HiDoc Technologies and Launch Digital Health App Cara Care
Germany-based Bayer AG (ETR: BAYN) has announced plans to acquire HiDoc Technologies GmbH in the...
Eli Lilly’s Imlunestrant Reduces Disease Progression in ER+/HER2- Advanced Breast Cancer: EMBER-3 Study
US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has published results from the Phase...
Fresenius Kabi Partners with Ori Biotech to Integrate IRO Platform with Cell Processing Systems
Germany-based Fresenius Kabi, a leading name in healthcare, has struck an accord with Ori Biotech...
Arvinas and Pfizer Present Positive TACTIVE-U Sub-Study Data at SABCS 2024
Partners Arvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. (NYSE: PFE) have jointly presented preliminary data...
GSK Enters Multi-Program Partnerships with Relation Therapeutics for Fibrotic Diseases and Osteoarthritis
UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has formed two multi-program strategic partnerships with compatriot...
Novartis’ Kisqali Shows Sustained Efficacy in NATALEE Study at SABCS 2024
Swiss pharmaceutical giant Novartis (NYSE: NVS) presented updated results from the pivotal Phase III NATALEE...
Legend Biotech’s Carvykti Demonstrates High MRD Negativity Rates in Phase III CARTITUDE-4 Trial
China-based Legend Biotech Corporation (NASDAQ: LEGN) has released new data on minimal residual disease (MRD)...
Huadong Medicine’s Arcalyst Receives NMPA Approval for Recurrent Pericarditis Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving another indication approval from the...
IMEIK Technology Receives NMPA Approval for Recombinant Human Hyaluronidase Clinical Study
China-based IMEIK Technology Development Co., Ltd (SHE: 300896) has announced receiving approval from the National...
Patronus Biotech’s RSV Vaccine LYB005 Receives NMPA Approval for Clinical Study
Guangzhou Patronus Biotech Co., Ltd., a vaccine start-up specializing in respiratory and infectious diseases, has...
Shanghai Pharmaceuticals’ SRD4610 Receives FDA Orphan Drug Designation for ALS Treatment
China’s Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced that the US Food and...
Sperogenix Therapeutics’ Agamree Receives NMPA Approval for Duchenne Muscular Dystrophy Treatment
China-based rare disease specialist Sperogenix Therapeutics Limited has announced receiving marketing approval from the National...
Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for SHR-4394 and HRS-3802 Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from...